Literature DB >> 9875200

Validation of a melanoma prognostic model.

D J Margolis1, A C Halpern, T Rebbeck, L Schuchter, R L Barnhill, J Fine, M Berwick.   

Abstract

BACKGROUND: A "clinically accessible," 4-variable (patient age, patient sex, tumor location, and tumour thickness) prognostic model has been published previously. This model evaluated variables that were commonly available to the clinician. Because models are heuristic, validity of a prognostic model should be evaluated in a population different from the original population.
OBJECTIVE: To evaluate the external validity of this 4-variable melanoma prognostic model.
DESIGN: To estimate the external validity of this model, we used a population-based cohort of individuals with melanoma. We also evaluated a 1-variable model (tumor thickness). Estimates of the external validity of these logistic regression models were made using the c statistic and the Brier score. SETTINGS AND PATIENTS: A total of 1261 patients with melanoma evaluated in a multispecialty, university-based practice and 650 patients with melanoma from throughout Connecticut. MAIN OUTCOME MEASURE: Death from melanoma within 5 years of diagnosis.
RESULTS: The c statistics for the 4-variable model were 0.86 (95% confidence interval [CI], 0.83-0.89) for the university-based practice data set and 0.81 (95% CI, 0.75-0.86) for the Connecticut data set. For thickness alone, the c statistics were 0.83 (95% CI, 0.80-0.86) and 0.79 (95% CI, 0.74-0.85), respectively. Brier scores for the 4-variable model were 0.09 (95% CI, 0.08-0.10) and 0.08 (95% CI, 0.06-0.09) and for the 1-variable model were 0.09 (95% CI, 0.08-0.10) and 0.08 (95% CI, 0.07-0.10), respectively. No significant differences exist between the data sets for the 4- and 1-variable models.
CONCLUSIONS: The 4- and 1-variable models are generalizable. The simpler 1-variable model--tumor thickness--can be used with a relatively small loss in accuracy.

Entities:  

Mesh:

Year:  1998        PMID: 9875200     DOI: 10.1001/archderm.134.12.1597

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  Total body skin examination for skin cancer screening among U.S. adults from 2000 to 2010.

Authors:  Naheed A Lakhani; Mona Saraiya; Trevor D Thompson; Sallyann Coleman King; Gery P Guy
Journal:  Prev Med       Date:  2014-01-10       Impact factor: 4.018

2.  Prevalence and correlates of skin cancer screening among middle-aged and older white adults in the United States.

Authors:  Elliot J Coups; Alan C Geller; Martin A Weinstock; Carolyn J Heckman; Sharon L Manne
Journal:  Am J Med       Date:  2010-05       Impact factor: 4.965

3.  Correspondence and correlates of couples' skin cancer screening.

Authors:  Carolyn J Heckman; Susan Darlow; Sharon L Manne; Deborah A Kashy; Teja Munshi
Journal:  JAMA Dermatol       Date:  2013-07       Impact factor: 10.282

4.  Melanoma survivorship: research opportunities.

Authors:  Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern
Journal:  J Cancer Surviv       Date:  2007-03       Impact factor: 4.442

5.  Skin cancer surveillance behaviors among US Hispanic adults.

Authors:  Elliot J Coups; Jerod L Stapleton; Shawna V Hudson; Amanda Medina-Forrester; Stephen A Rosenberg; Marsha Gordon; Ana Natale-Pereira; James S Goydos
Journal:  J Am Acad Dermatol       Date:  2012-11-19       Impact factor: 11.527

6.  Skin surveillance intentions among family members of patients with melanoma.

Authors:  Elliot J Coups; Sharon L Manne; Paul B Jacobsen; Michael E Ming; Carolyn J Heckman; Stuart R Lessin
Journal:  BMC Public Health       Date:  2011-11-14       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.